Subcutaneous immune checkpoint inhibitors: A new era in oncology care

Abstract

Keywords

Immune checkpoint inhibitors oncology cancer care subcutaneous administration

Get full access to this article

View all access options for this article.

References

Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph) [prescribing information]. Rahway, NJ: Merck Sharp & Dohme LLC, September 2025.

Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company, December 2024.

Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) [prescribing information]. South San Francisco, CA: Genentech, Inc, September 2024.

Keytruda (pembrolizumab) [prescribing information]. Rahway, NJ: Merck Sharp & Dohme LLC, August 2025.

Opdivo (nivolumab) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company, June 2025.

Tecentriq (atezolizumab) [prescribing information]. South San Francisco, CA: Genentech, Inc, October 2025.

Locke

Maneval

LaBarre

. ENHANZE® drug delivery technology: a novel approach to subcutaneous administration using recombinant human hyaluronidase PH20. Drug Deliv 2019; 26: 98–106.

George

Bourlon

Overman

, et al. Systematic literature review of intravenous versus subcutaneous administration of oncology therapies: a clinical, economic and patient perspective. Cancer Treat Rev 2025; 139: 102974.